Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency
Br J Dermatol
.
2021 Apr;184(4):770-772.
doi: 10.1111/bjd.19684.
Epub 2020 Dec 28.
Authors
L H Frommherz
1
,
C M Schempp
1
,
C Has
1
Affiliation
1
Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
PMID:
33205394
DOI:
10.1111/bjd.19684
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Antibodies, Monoclonal, Humanized*
Dermatitis, Exfoliative*
Desmogleins
Humans
Substances
Antibodies, Monoclonal, Humanized
Desmogleins
secukinumab
Grants and funding
Else-Kröner Fresenius Foundation
PPRC-2018-65/European Academy of Dermatology and Veneorology